AR048341A1 - Moduladores cannabinoides de tetrahidro-indazol - Google Patents

Moduladores cannabinoides de tetrahidro-indazol

Info

Publication number
AR048341A1
AR048341A1 ARP050101196A ARP050101196A AR048341A1 AR 048341 A1 AR048341 A1 AR 048341A1 AR P050101196 A ARP050101196 A AR P050101196A AR P050101196 A ARP050101196 A AR P050101196A AR 048341 A1 AR048341 A1 AR 048341A1
Authority
AR
Argentina
Prior art keywords
hydroxy
halogen
positions
optionally substituted
alkylene
Prior art date
Application number
ARP050101196A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34965110&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR048341(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR048341A1 publication Critical patent/AR048341A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente trata de moduladores cannabinoides de tetrahidroindazol, y un método para usarlo en el tratamiento, mejoramiento o prevencion de un sindrome, desorden o enfermedad intermediado por un receptor cannabinoide. Reivindicacion 1: Un compuesto que tiene una estructura de acuerdo con la formula (1): en la cual la línea punteada entre las posiciones 2-3 y las posiciones 3a-7a en la formula (1) representan ubicaciones para los dos dobles enlaces presentes cuando X1R1 está presente; las líneas punteadas entre las posiciones 3-3a y las posiciones 7a-1 en la formula (1) representan ubicaciones para los dos dobles enlaces presentes cuando está presente X2R2; la línea punteada entre las posiciones 7 y X4R4 en la formula (1) representa la ubicacion para un doble enlace; X1 está ausente o es alquileno inferior; X2 está ausente o es alquileno inferior; donde unicamente están presentes uno de X1R1 y X2R2; X3 está ausente, o es alquileno inferior, alquilideno inferior o -NH- ; cuando la línea punteada entre las posiciones 7 y X4R4 está ausente, X4 está ausente o es alquileno inferior; cuando la línea punteada entre las posiciones 7 y X4R4 está presente, X4 está ausente; X5 está ausente o es alquileno inferior; R1 está seleccionado del grupo que consiste en arilo, cicloalquilo C3-12, o heterociclilo, cualquiera de los cuales está opcionalmente sustituido en una o más posiciones con halogeno, alquilo inferior, hidroxi o alcoxi inferior; R2 está seleccionado del grupo que consiste en arilo, cicloalquilo C3-12, o heterociclilo, cualquiera de los cuales está opcionalmente sustituido en una o más posiciones con halogeno, alquilo inferior, hidroxi o alcoxi inferior; R3 es como se muestra en el grupo de formulas (2), cuando la línea punteada entre las posiciones 7 y X4R4 está ausente, R4 es H, hidroxi, alquilo inferior, alcoxi inferior, halogeno, arilo opcionalmente sustituido en una o más posiciones con hidroxi, alquilo inferior, alcoxi inferior o halogeno, heterociclilo opcionalmente sustituido en una o más posiciones con hidroxi, alquilo inferior, alcoxi inferior o halogeno, o cicloalquilo C3-12 opcionalmente sustituido en una o más posiciones con hidroxi, alquilo inferior, alcoxi inferior o halogeno; cuando la línea punteada entre las posiciones 7 y X4R4 está presente, R4 es CH-arilo es donde arilo está opcionalmente sustituido en una o más posiciones con hidroxi, alquilo inferior, alcoxi inferior o halogeno; o CH-heterociclilo en donde el heterociclilo está opcionalmente sustituido en una o más posiciones con hidroxi, alquilo inferior, alcoxi inferior o halogeno; R5 es H, hidroxi, alquilo inferior, alcoxi inferior, hidroxi-alquileno inferior-carboxi, alcoxicarbonilo, ariloxicarbonilo, aril-alcoxicarbonilo, NHR10, C(O)NR11R11a, -O-C(O)-R12, oxo, o -C(O)R13; R6 está ausente, o es -CH(R6a)-; R6a es H, alquilo inferior, o arilo opcionalmente sustituido con uno o más de halogeno, hidroxi, alcoxi inferior, carboxi o alcoxicarbonilo; R7 es alcoxi inferior, arilo opcionalmente sustituido con uno más hidroxi, halogeno, alquilo inferior, carboxi, alcoxicarbonilo, alcoxi inferior, hidroxi-alquileno-, -NH(R6a), ariloxi, arilalcoxi, o aril-alquileno inferior, cicloalquilo C3-12 opcionalmente sustituido con uno o mas hidroxi, halogeno, alquilo inferior, alquilo inferior-aminocarbonilo, carboxi, alcoxicarbonilo, alcoxi inferior, alcoxi inferior-alquileno inferior, hidroxi-alquileno-, ariloxi, arilalcoxi, arilalcoxi-alquileno inferior- opcionalmente sustituido en el arilo con uno o más hidroxi, halogeno o alquilo inferior, o aril-alquileno inferior, heterociclilo opcionalmente sustituido con uno o más hidroxi, halogeno, alquilo inferior, carboxi, alcoxicarbonilo, alcoxi inferior, alcoxi inferior-alquileno inferior-, hidroxi-alquileno-, ariloxi o arilalcoxi; R8, R8a, R9 y R9a, son cada uno individualmente H, alquilo inferior, -NHR15, arilo opcionalmente sustituido con uno o más hidroxi, halogeno, -NH(R6a), -SO2-NH(R6a), alquilo inferior, carboxi, alcoxicarbonilo, alcoxi inferior, hidroxi-alquileno-, ariloxi o arilalcoxi, cicloalquilo C3-12 opcionalmente sustituido con uno o más hidroxi, halogeno, amino, alquilo inferior, carboxi, alcoxicarbonilo, alcoxi inferior, hidroxi-alquileno-, ariloxi, arilalcoxi, o alquileno inferior, o heterociclilo opcionalmente sustituido con uno o más hidroxi, halogeno, amino, alquilo inferior, carboxi, alcoxicarbonilo, alcoxi inferior, hidroxi- alquileno-, ariloxi o arilalcoxi; R10 es H, alcoxicarbonilo C1-10 opcionalmente sustituido en una o más posiciones con hidroxi, halogeno o arilo, -C(O)CF3, -SO2-NR14R14a, -C(O)-heterociclilo opcionalmente sustituido en una o más posiciones con hidroxi, halogeno, o arilo, -C(O)NR14R14a, -SO2-arilo, -SO2R14, o SO2NR14R14a, R11, R11a, R12, R13, R14 y R14a y R15 son cada uno individualmente H, alquilo C1-10, heterociclilo, cicloalquilo C3-12, o arilo opcionalmente sustituido con alquilo inferior, hidroxi, alcoxi, halogeno-SO2-N(R6a)2, heterociclilo o aril-alquileno inferior-; Z1 está ausente, -NH-, o es alquileno inferior opcionalmente sustituido en una o más posiciones con halogeno, hidroxi,. alcoxi inferior, carboxi o alcoxicarbonilo inferior; Z2 está ausente, o es alquileno inferior opcionalmente sustituido en una o más posiciones con arilo, cicloalquilo, halogeno, hidroxi, alquilo inferior, alcoxi inferior, carboxi, alcoxicarbonilo o arilo, o una sal, isomero, profármaco, metabolito o polimorfo farmacéuticamente aceptable del mismo.
ARP050101196A 2004-03-24 2005-03-28 Moduladores cannabinoides de tetrahidro-indazol AR048341A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55589004P 2004-03-24 2004-03-24

Publications (1)

Publication Number Publication Date
AR048341A1 true AR048341A1 (es) 2006-04-19

Family

ID=34965110

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050101196A AR048341A1 (es) 2004-03-24 2005-03-28 Moduladores cannabinoides de tetrahidro-indazol

Country Status (22)

Country Link
US (2) US7452997B2 (es)
EP (1) EP1735286B1 (es)
JP (1) JP4825792B2 (es)
CN (1) CN1956964B (es)
AR (1) AR048341A1 (es)
AT (1) ATE540027T1 (es)
AU (1) AU2005228868B2 (es)
BR (1) BRPI0509207A (es)
CA (1) CA2561305C (es)
CR (1) CR8701A (es)
DK (1) DK1735286T3 (es)
EA (1) EA010887B1 (es)
EC (1) ECSP066877A (es)
ES (1) ES2378071T3 (es)
IL (1) IL178290A0 (es)
MX (1) MXPA06011017A (es)
NO (1) NO20064810L (es)
PL (1) PL1735286T3 (es)
PT (1) PT1735286E (es)
TW (1) TW200602324A (es)
WO (1) WO2005095353A1 (es)
ZA (1) ZA200608808B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2875230A1 (fr) * 2004-09-13 2006-03-17 Sanofi Aventis Sa Derives de pyrazole condense, leur preparation et leur application en therapeutique
US7888381B2 (en) * 2005-06-14 2011-02-15 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
CN101312725B (zh) * 2005-09-23 2012-01-11 詹森药业有限公司 六氢-环辛四烯并吡唑***素调节剂
RS52195B (en) * 2005-09-23 2012-10-31 Janssen Pharmaceutica N.V. MODULATOR HEXA HYDROCYCLOHEPTAPIRAZOLE Cannabinoids
EA200800888A1 (ru) * 2005-09-23 2009-02-27 Янссен Фармацевтика Н.В. Модуляторы каннабиноидов на основе замещенных 3-амидотетрагидроиндазолилов
US8378117B2 (en) 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
US7825151B2 (en) * 2005-09-23 2010-11-02 Janssen Pharmaceutica Nv Hexahydro-cyclooctyl pyrazole cannabinoid modulators
US8378096B2 (en) 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
EP1937646A1 (en) * 2005-09-23 2008-07-02 Janssen Pharmaceutica N.V. Tetrahydro-cyclopentyl pyrazole cannabinoid modulators
US7795294B2 (en) 2006-02-14 2010-09-14 Janssen Pharmaceutica N.V. Tetrahydro-2H-indazole pyrazole cannabinoid modulators
WO2007112402A1 (en) * 2006-03-27 2007-10-04 Janssen Pharmaceutica N.V. Tetrahydro-1h-1,2,6-triaza-azulene cannabinoid modulators
US20070254911A1 (en) * 2006-03-27 2007-11-01 Mingde Xia Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators
US20080299210A1 (en) * 2006-04-13 2008-12-04 Min Wei Stable nanosized amorphous drug
RU2009117203A (ru) * 2006-11-03 2010-12-10 Гленмарк Фармасеутикалс С.А. (Ch) Новые лиганды каннабиноидных рецепторов, фармацевтические композиции, содержащие данные лиганды, и способы их получения
EP1935420A1 (en) * 2006-12-21 2008-06-25 Merck Sante 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors
JP2010522182A (ja) * 2007-03-21 2010-07-01 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｃｂ２受容体介在疼痛を処置する方法
CA2681381A1 (en) * 2007-03-21 2008-09-25 Janssen Pharmaceutica N.V. Method for treating cb2 receptor mediated pain
UA100120C2 (en) 2007-04-03 2012-11-26 Анадис Фармасьютикалз, Инк. 5,6-dihydro-1h-pyridin-2-one compounds
US8338623B2 (en) * 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
US7943653B2 (en) * 2007-08-13 2011-05-17 Janssen Pharmaceutica N.V. Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators
WO2009087564A1 (en) * 2008-01-08 2009-07-16 Purdue Pharma L.P. Proline analogs as ligands for cannabinoid receptors for the treatment of pain
US20090215850A1 (en) * 2008-02-27 2009-08-27 Mingde Xia Method for treating cb2 receptor mediated pain
CA2735886A1 (en) * 2008-09-25 2010-04-01 F. Hoffmann-La Roche Ag Indazole or 4,5,6,7-tetrahydro-indazole derivatives
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10435375B2 (en) 2015-05-05 2019-10-08 Northwestern University CXCR4 chemokine receptor modulators
WO2017034872A1 (en) * 2015-08-25 2017-03-02 Janssen Pharmaceutica Nv Indazole derivatives useful as cb-1 inverse agonists
CN105367498B (zh) * 2015-11-11 2019-05-17 中国农业大学 吡唑并环-3-甲酰胺类似物及其制备和应用
CN106397218A (zh) * 2016-09-04 2017-02-15 王际菊 S‑α‑环己基苯甲胺
WO2020008317A1 (en) * 2018-07-03 2020-01-09 Janssen Pharmaceutica Nv Acylsufonamide compounds useful as ep3 receptor antagonists
CN114391011A (zh) * 2019-09-12 2022-04-22 四川海思科制药有限公司 一种六氢化苯并吡唑衍生物及其制备
CN114391010A (zh) * 2019-09-12 2022-04-22 四川海思科制药有限公司 一种三环吡唑衍生物及其制备
KR20230027161A (ko) * 2020-06-11 2023-02-27 베타 파머수티컬 컴퍼니 리미티드 비시클릭 화합물 및 이의 응용

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1052111B (it) * 1972-02-29 1981-06-20 Acraf Acidi i benzil i h indazol 3 carbossilici sostituiti e loro derivati
US3895025A (en) * 1973-03-29 1975-07-15 Du Pont 2-Benzimidazolethiol preparation
US4851425A (en) * 1985-06-14 1989-07-25 The Upjohn Company Cyclopentapyrazole and tetrahydroindazole compounds and their use as anti-inflammatory and anti-allergic agents
US4861777A (en) * 1987-09-11 1989-08-29 Mitsubishi Kasei Corporation Pyrazole derivative and insecticidal and miticidal composition containing the derivative as active ingredient
JPH06306053A (ja) * 1993-01-29 1994-11-01 Sagami Chem Res Center ３−アゾールカルボン酸誘導体の製造方法及びその中間体
US5532237A (en) * 1995-02-15 1996-07-02 Merck Frosst Canada, Inc. Indole derivatives with affinity for the cannabinoid receptor
US6410533B1 (en) * 2000-02-10 2002-06-25 Genzyme Corporation Antibacterial compounds
JP2004502642A (ja) * 2000-02-11 2004-01-29 ブリストル−マイヤーズ　スクイブ　カンパニー カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用
CN1589269A (zh) 2001-10-26 2005-03-02 康涅狄格大学 杂1,2－二氢化茚:一类新型有效的***配体
JP2005527586A (ja) * 2002-04-05 2005-09-15 メルク　エンド　カムパニー　インコーポレーテッド 置換アリールアミド
US7145012B2 (en) * 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof

Also Published As

Publication number Publication date
PT1735286E (pt) 2012-03-05
DK1735286T3 (da) 2012-04-02
EP1735286B1 (en) 2012-01-04
US20090099143A1 (en) 2009-04-16
EP1735286A1 (en) 2006-12-27
CR8701A (es) 2008-11-24
US7452997B2 (en) 2008-11-18
ECSP066877A (es) 2006-11-24
MXPA06011017A (es) 2007-03-21
IL178290A0 (en) 2006-12-31
US20050228034A1 (en) 2005-10-13
ATE540027T1 (de) 2012-01-15
EA010887B1 (ru) 2008-12-30
CA2561305A1 (en) 2005-10-13
BRPI0509207A (pt) 2007-08-28
JP2007530577A (ja) 2007-11-01
CA2561305C (en) 2013-07-30
CN1956964A (zh) 2007-05-02
WO2005095353A1 (en) 2005-10-13
CN1956964B (zh) 2011-06-15
AU2005228868A1 (en) 2005-10-13
JP4825792B2 (ja) 2011-11-30
PL1735286T3 (pl) 2012-06-29
NO20064810L (no) 2006-12-22
TW200602324A (en) 2006-01-16
ZA200608808B (en) 2008-06-25
ES2378071T3 (es) 2012-04-04
AU2005228868B2 (en) 2012-02-09
EA200601760A1 (ru) 2007-02-27

Similar Documents

Publication Publication Date Title
AR048341A1 (es) Moduladores cannabinoides de tetrahidro-indazol
PE20230249A1 (es) Compuestos de heteroarilo biciclicos y usos de estos
PE20221336A1 (es) Compuestos triciclicos sustituidos
AR039570A1 (es) Antagonistas de los receptores de trombina
AR119046A1 (es) Inhibidores heterobicíclicos de mat2a y su uso para el tratamiento de diversos tipos de cáncer
AR068496A1 (es) Piperidinas sustituidas, una composicion farmaceutica que las comprende y su uso para el tratamiento de enfermedades mediadas por la modulacion de la actividad de gpr119.
RS52245B (en) CYTOTOXIC AGENTS CONTAINING NEW TOMAIMYCIN DERIVATIVES AND THEIR THErapeutic Use
CO6220853A2 (es) Derivados de pentafluorotiobenzamido acetonitrilo como agentes antiparasitarios
AR049894A1 (es) Derivados de prolina y sus usos como inhibodores de la enzima dipeptidilpeptidasa-iv
CO6160237A2 (es) Pirazinonas y pirazinoles sustituidos y composiciones que los comprenden
AR052943A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
AR047098A1 (es) Derivados de arilanilina como agonistas del receptor adrenergico beta2
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
DOP2009000232A (es) Metanoisoindoles y dionas de éstos como agentes anti-psicóticos.
AR040047A1 (es) 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de la 5-hidroxitriptamina-6
JP2008526999A5 (es)
AR056980A1 (es) Derivados de dihidrobenzofurano, composiciones farmaceuticas, y uso de los mismos
AR047545A1 (es) Compuestos derivados de carbonilamino biciclicos como antagonistas del receptor de quimiocina, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos en combinacion con otros agentes terapeuticos para el tratamiento de inflamaciones, enf
AR087607A1 (es) Derivados de piridazinona
PE20090700A1 (es) Compuestos heterociclicos como antagonistas del receptor opioide periferico
AR046313A1 (es) Compuesto de 2-cianopirrolidincarboxamida, un metodo para su obtencion y su empleo en composiciones farmaceuticas y en medicamentos con actividad inhibitoria de la dipeptidil peptidasa-iv (dpp-iv).
AR091781A1 (es) Antagonistas del receptor de 5-ht3
AR051952A1 (es) Compuestos de n- sulfonilaminobencil - 2- fenoxicetamida sustituidos
AR046926A1 (es) Combinaciones de inhibidor de erbb2 selectivo/anticuerpos anti-erbb en el tratamiento del cancer
AR067412A1 (es) Moduladores de propiedades farmaceuticas de productos terapeuticos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal